Table 1.

Patients' characteristics before TIL therapy

PatientGenderAt diagnosisDiagnosis to ACT (y)*Prior treatments for stage IV disease
AgeStageSite of metastasisTreatment (not incl. IL-2)IL-2–based treatmentResponse to IL-2 treatmentTTP (mo)
Responders
05-LAM39M1aSC2SurgeryCBPDNa
19-NSM50IIbNa16TaxolCBPDNa
03-MGM26IbNa10CBPDNa
06-TSM55IIINa5HD bolusSD6
09-SDM44IIbNa1CBPDNa
13-BSM57IIbNa4CBSD7
14-SVM69IIINa2.3SurgeryCBPDNa
16-SHM38IIINa2.8TaxolCBPDNa
18-WRF68IIINa2.2SurgeryCBPR5
20-TYM55IIINa3.3SurgeryCBCR5
Median3.15.5
Nonresponders
01-AYM51M1aSC5.3CBSD14
07-ZRM20IIINa1.8CBPDNa
08-RMF31IaNa2.8CBPR2
12-VSF36IIINa5.5SurgeryCBSD2
02-PEM33IIINa3DacarbacineCBPDNa
04-BAM41IIINa16.3SurgeryCBPR16
10-BEF48IIINa4.8CBPDNa
11-KBM55IIINa2.4CBPDNa
15-SMM52M1cLiver, boneNaTaxolCBPDNa
17-ZDF46IbNa22CBPDNa
Median4.88.0
P = 0.58P = 0.47

Abbreviations: TTP, time to progression; CB, chemobiotherapy consisting of IL-2, dacarbazine, and cisplatin; HD, high-dose; Na, not applicable.

  • *Years from diagnosis to adoptive cell transfer.